Psilocybin therapeutic use program established; protections for registered patients, registered suppliers, registered facilitators, and health care practitioners established; civil actions authorized; advisory committee established; and money appropriated.
HF4577 would create a state-regulated psilocybin therapeutic use program for Minnesota residents age 21 and older who have a qualifying medical condition and are certified by a licensed health care practitioner. The bill sets up a framework for enrollment, informed consent, patient registries, facilitator licensing, supplier cultivation, testing standards, treatment facilities, and supervised administration sessions. It also allows preparation and integration sessions, requires the Department of Health to adopt rules, and directs the commissioner to work with a research institution and a Psychedelic Medicine Advisory Committee to shape the program and evaluate outcomes.
The bill also removes psilocybin from Minnesota’s Schedule I controlled substances list and places psilocybin and psilocin in Schedule IV, while preserving criminal penalties for diversion outside the program. In addition to the program structure, the bill creates legal protections for registered patients, suppliers, facilitators, and health care practitioners, including limits on forfeiture, restrictions on law enforcement access to registry data, employment and housing protections, and civil remedies for violations. It also includes public education, first responder training, data privacy provisions, fees, and an appropriation for implementation and research.
The bill would substantially change Minnesota controlled-substance law by reclassifying psilocybin and psilocin from Schedule I to Schedule IV and by creating new chapter 152 provisions governing lawful therapeutic use. It would authorize the Department of Health, in coordination with the Office of Cannabis Management, to license and regulate patients, facilitators, suppliers, testing facilities, and treatment facilities, while also establishing data practices, fee collection, and rulemaking authority. The bill would affect health care practitioners, mental health professionals, cultivators, law enforcement, employers, landlords, schools, and child custody determinations by creating specific protections and limits tied to lawful participation in the program.
Because there were no recorded committee transcripts or votes provided, the bill’s sentiment must be inferred from its structure and caption. The measure appears broadly supportive of regulated therapeutic access to psilocybin, with a strong emphasis on safety, screening, oversight, and research rather than unrestricted legalization. The detailed safeguards, limited initial rollout, and data collection requirements suggest an approach designed to reassure policymakers concerned about public health and diversion while advancing access for patients with serious conditions.
The main points of contention likely center on whether psilocybin should be reclassified at all, whether Minnesota should authorize therapeutic use before broader federal acceptance, and how much risk the state should assume in allowing supervised use of a currently controlled hallucinogen. Other likely concerns include the adequacy of medical screening, the qualifications and oversight of facilitators, the use of home-based administration, privacy of patient registry data, and the scope of employment, housing, education, and custody protections. The bill’s inclusion of criminal penalties for diversion and its limits on access by minors, schools, and correctional facilities indicate that supporters anticipated concerns about misuse and public safety.